

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31ST MARCH, 2009

(Rs.in Lacs)

Sr. No.	Particulars	Quarter ended 31/03/2009	Corresponding Quarter ended 31/03/2008	For the Year Ended 31/12/2008
		Unaudited	Unaudited	Audited
1	Income			
	a) Net Sales/Income from Operations	34,957.49	26,903.61	117,838.07
	b) Other Operating Income	163.15	218.42	1,003.26
	c) Total	35,120.64	27,122.03	118,841.33
2	Expenditure			
	a) ((Increase)/decrease in stock in trade and work in progress	(4,523.32)	(1,698.07)	313.09
	b) Consumption of raw materials	18,559.59	10,787.18	42,153.95
	c) Employees Cost	972.24	842.36	3,522.48
	d) Depreciation	3,006.93	2,462.46	10,715.18
	e) Other expenditure	6,792.54	4,952.30	21,718.36
	f) Total	24,807.98	17,346.23	78,423.06
3	Profit from Operations before Other Income and Interest (1-2)	10,312.66	9,775.80	40,418.27
4	Other Income	0.00	0.00	0.00
5	Profit before Interest (3+4)	10,312.66	9,775.80	40,418.27
6	Interest	2,994.20	1,172.78	5,920.71
7	Profit (+) / Loss (-) from Ordinary Activities before tax (5-6)	7,318.46	8,603.02	34,497.56
8	Tax expense			
	a) Current	850.00	950.00	3,750.00
	b) Deffered	1,400.00	1,850.00	7,550.00
	c) Fringe Benefit	12.50	11.00	47.50
	d) Total	2,262.50	2,811.00	11,347.50
9	Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)	5,055.96	5,792.02	23,150.06
10	Extraordinary Items	283.16	283.16	1,132.64
11	Net Profit (+)/Loss (-) for the period (9-10)	4,772.80	5,508.86	22,017.42
12	Prior year adjustment	0.00	0.00	99.29
13	Profit available for appropriation	4,772.80	5,508.86	21,918.13
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,488.22	2,294.76	2,437.98
15	Reserves excluding Revaluation Reserves as per balance sheet.			170,359.64
16	Earnings Per Share (EPS)			
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	2.03	2.52	9.50
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.92	2.40	9.03
17	Public Shareholding			
	- Number of shares	132,291,603	112,945,515	127,267,548
	- Percentage of shareholding	53.17%	49.22%	52.20%
18	Promoters and Promoter Group Shareholding			
	a) Pledged/Encumbered			
	Number of shares	32,488,136		32,488,136
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	36.49%		36.49%
	Percentage of shares (as a % of the total share capital of the Company)	13.06%		13.33%
	b) Non-encumbered			
	Number of shares	56,546,558		56,546,558
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	63.51%		63.51%
	Percentage of shares (as a % of the total share capital of the Company)	22.73%		23.19%

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31ST MARCH, 2009

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 29th April, 2009.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31st March, 2009
- 4 During the Quarter the Company has issued 5,024,055 equity shares of Re.1/- each pursuant to conversion of FCCBs.
- 5 The number of investor complaints for the quarter ended on 31st March , 2009 were : Opening - 2, Received - 12, Disposed off - 13, and Balance - 1.
- 6 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 29th April, 2009

Nitin J. Sandesara
Chairman & Managing Director